Modeling HSV-1 Latency and Reactivation Using hiPSC-Derived Sensory Neurons

Study Background and Research Question

Herpes simplex virus 1 (HSV-1) is a widespread pathogen, establishing lifelong latent infection in peripheral neurons following initial lytic replication in mucosal epithelial cells. Periodic reactivation from latency causes recurrent disease, ranging from cold sores to life-threatening conditions such as encephalitis. While animal models have historically dominated HSV latency research, significant species-specific differences limit translational accuracy. There is a critical need for robust, scalable human neuronal models to dissect the molecular mechanisms underpinning HSV-1 latency and reactivation (paper).

Key Innovation from the Reference Study

Oh et al. (2025) present a validated protocol to rapidly generate functional human sensory neurons from inducible pluripotent stem cells (hiPSCs), and demonstrate that these neurons can support both latent infection and controlled reactivation of HSV-1. The study’s innovation lies in (1) the scalability and reproducibility of the differentiation protocol, and (2) the direct demonstration that human-derived neurons recapitulate key features of HSV-1 latency previously observed only in animal models (paper).

Methods and Experimental Design Insights

The researchers employed a stepwise differentiation protocol to convert hiPSCs into excitable sensory neurons expressing functional ion channels. The system was optimized for both rapid differentiation and scalability, enabling sufficient cell numbers for virological assays. Following differentiation, neurons were exposed to HSV-1 under conditions designed to favor latent infection. Latency was verified by several orthogonal measures: absence of infectious virus, suppression of lytic gene expression, robust expression of latency-associated transcripts (LATs), and demonstration of viral genome heterochromatinization.

To test reactivation, neurons were treated with established pharmacological triggers, such as forskolin and PI3 kinase inhibitors. Successful reactivation was marked by resumption of lytic gene expression and production of infectious virus, thereby confirming the functional relevance of the model to the human context (paper).

Core Findings and Why They Matter

• Scalable Human Neuron Differentiation: The protocol reproducibly yielded sensory neurons with electrophysiological properties and ion channel expression reflective of native peripheral neurons (paper).
• Latent HSV-1 Infection Established: Infected neurons showed no release of infectious particles, reduced lytic gene expression, efficient LAT expression, and heterochromatinization of the viral genome—hallmarks of latency as defined in vivo (paper).
• Reactivation Triggers Recapitulated: Forskolin and PI3K inhibitor treatments induced reactivation, as evidenced by increased lytic gene transcription and infectious virus production, mirroring known reactivation stimuli (paper).

This model bridges a longstanding gap in HSV research: the ability to interrogate latency and reactivation mechanisms in a renewable, human-relevant neuronal system. Importantly, it provides a platform for dissecting neuron-intrinsic regulatory mechanisms and for screening candidate therapeutics targeting latent infection stages—an unmet clinical need, as no drugs currently clear latent HSV-1 (paper).

Comparison with Existing Internal Articles

While the reference study focuses on viral latency in neuronal models, recent internal reviews of SB 431542—a potent and selective ALK5 inhibitor targeting the TGF-β pathway—provide complementary insights for researchers. For example, one review details SB 431542’s use in controlling TGF-β-mediated processes, including cell fate, immune modulation, and co-culture modeling. Another internal synthesis outlines strategic protocols for TGF-β pathway inhibition in organoid and immune studies, underscoring the compound’s reproducibility and translational value.

Though the current HSV-1 study does not directly manipulate TGF-β signaling, the established hiPSC-derived neuron platform could, in principle, be adapted to probe the intersection of neuroimmune signaling and viral latency. SB 431542 and similar TGF-β signaling pathway inhibitors are often used in neuron differentiation protocols or for dissecting glial-neuronal interactions, as highlighted in previous workflow recommendations (internal review).

Limitations and Transferability

This model’s principal limitation is its focus on neuron-intrinsic mechanisms; it does not incorporate the full complexity of ganglionic microenvironments, including glial and immune components. While the differentiation protocol is scalable and reproducible, subtle differences in hiPSC lines may influence differentiation efficiency or neuronal subtype specification, potentially affecting viral latency dynamics (paper). Furthermore, reactivation stimuli are pharmacological and may not fully recapitulate physiological triggers in vivo.

Nonetheless, the system provides a robust platform for initial mechanistic studies and drug screening, with the potential for future co-culture or organoid adaptation to address multi-cellular interactions.

Protocol Parameters

• assay | hiPSC sensory neuron differentiation | 14–21 days | scalable model for functional neuron generation | protocol validated by electrophysiology and marker expression | paper
• assay | HSV-1 latent infection | MOI 0.1–1, 7–14 days latency | establishment of latency in human neurons | verified by absence of infectious virus, LAT expression, genome heterochromatinization | paper
• assay | Reactivation trigger (forskolin, PI3Ki) | 24–48 hours post-latency | induces HSV-1 reactivation | increases lytic gene expression and infectious virus output | paper
• assay | TGF-β pathway inhibition (SB 431542) | 1–10 μM (workflow recommendation) | optional use during neuron differentiation or functional studies | modulates TGF-β signaling, supports specific lineage outcomes or signaling research | workflow_recommendation

Why this cross-domain matters, maturity, and limitations

The bridge between HSV-1 latency research and TGF-β pathway modulation is still nascent, as direct crosstalk was not addressed in the primary study. However, the established utility of TGF-β signaling pathway inhibitors (such as SB 431542) in neurodevelopmental and immunological modeling suggests potential for future cross-domain investigations. Careful protocol optimization and multi-line validation are recommended for such applications (internal review).

Research Support Resources

For researchers seeking to replicate or extend hiPSC-based neuronal workflows, validated small molecule reagents are critical. SB 431542 (SKU A8249) from APExBIO is a widely used, selective ALK5 inhibitor for TGF-β pathway modulation, supporting studies of cell fate, proliferation, and immune signaling in neuronal and co-culture models (product_spec). When integrating TGF-β inhibition into differentiation or functional assays, consult published protocols and optimize conditions for your specific cell system.